| |  Online-Ressource |
|---|
| Verfasst von: | Christopeit, Maximilian Erich Joachim [VerfasserIn]  |
|---|
| | Schmidt-Hieber, Martin [VerfasserIn] |
|---|
| | Sprute, Rosanne [VerfasserIn] |
|---|
| | Buchheidt, Dieter [VerfasserIn] |
|---|
| | Hentrich, Marcus [VerfasserIn] |
|---|
| | Karthaus, Meinolf [VerfasserIn] |
|---|
| | Penack, Olaf [VerfasserIn] |
|---|
| | Ruhnke, Markus [VerfasserIn] |
|---|
| | Weißinger, Florian [VerfasserIn] |
|---|
| | Cornely, Oliver Andreas [VerfasserIn] |
|---|
| | Maschmeyer, Georg [VerfasserIn] |
|---|
| Titel: | Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) |
|---|
| Verf.angabe: | Maximilian Christopeit, Martin Schmidt-Hieber, Rosanne Sprute, Dieter Buchheidt, Marcus Hentrich, Meinolf Karthaus, Olaf Penack, Markus Ruhnke, Florian Weissinger, Oliver A. Cornely, Georg Maschmeyer |
|---|
| Jahr: | 2021 |
|---|
| Jahr des Originals: | 2020 |
|---|
| Umfang: | 16 S. |
|---|
| Fussnoten: | Gesehen am 22.04.2021 ; Published Online: 20 October 2020 |
|---|
| Titel Quelle: | Enthalten in: Annals of hematology |
|---|
| Ort Quelle: | Berlin : Springer, 1991 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 100(2021), 2, Seite 321-336 |
|---|
| ISSN Quelle: | 1432-0584 |
|---|
| Abstract: | To ensure the safety of high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT), evidence-based recommendations on infectious complications after HDC/ASCT are given. This guideline not only focuses on patients with haematological malignancies but also addresses the specifics of HDC/ASCT patients with solid tumours or autoimmune disorders. In addition to HBV and HCV, HEV screening is nowadays mandatory prior to ASCT. For patients with HBs antigen and/or anti-HBc antibody positivity, HBV nucleic acid testing is strongly recommended for 6 months after HDC/ASCT or for the duration of a respective maintenance therapy. Prevention of VZV reactivation by vaccination is strongly recommended. Cotrimoxazole for the prevention of Pneumocystis jirovecii is supported. Invasive fungal diseases are less frequent after HDC/ASCT, therefore, primary systemic antifungal prophylaxis is not recommended. Data do not support a benefit of protective room ventilation e.g. HEPA filtration. Thus, AGIHO only supports this technique with marginal strength. Fluoroquinolone prophylaxis is recommended to prevent bacterial infections, although a survival advantage has not been demonstrated. |
|---|
| DOI: | doi:10.1007/s00277-020-04297-8 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1007/s00277-020-04297-8 |
|---|
| | DOI: https://doi.org/10.1007/s00277-020-04297-8 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1755733313 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) / Christopeit, Maximilian Erich Joachim [VerfasserIn]; 2021 (Online-Ressource)
